secwatch / observer
8-K filed February 1, 2024, 6:59 PM ET ticker TVGN CIK 0001860871
M&A confidence high sentiment positive materiality 0.75

Semper Paratus shareholders approve merger with Tevogen Bio; redemptions ~$15.9M

Tevogen Bio Holdings Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Tevogen Bio Holdings Inc. shareholders approved Proposal No. 4(A) — Advisory Charter Proposal to increase authorized share capital to 800,000,000 shares of common stock and 20,000,000 shares of preferred stock at the 2024-01-31 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2024-01-31
Exact text from the filing
A proposal to increase the authorized share capital of Semper Paratus to 800,000,000 shares of common stock, par value $0.0001 per share, of New Tevogen and 20,000,000 shares of preferred stock, par value $0.0001 per share, of New Tevogen: For Against Abstain Broker Non-Votes 13,840,594 143,495 0 n/a
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Tevogen Bio Holdings Inc. shareholders approved Proposal No. 3 — The Organizational Documents Proposal at the 2024-01-31 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2024-01-31
Exact text from the filing
Proposal No. 3 — The Organizational Documents Proposal — The approval of the Organizational Documents Proposal required the affirmative vote of two-thirds (2/3) of the votes of the votes cast by holders of Semper Paratus’ ordinary shares present in person or represented by proxy and entitled to vote at the Meeting. The following is a tabulation of the votes with respect to this proposal, which was approved by Semper Paratus’ shareholders: For Against Abstain Broker Non-Votes 13,840,594 143,495 0 n/a
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Tevogen Bio Holdings Inc. shareholders approved Proposal No. 2 — The Domestication Proposal at the 2024-01-31 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2024-01-31
Exact text from the filing
Proposal No. 2 — The Domestication Proposal — The approval of the Domestication Proposal required the affirmative vote of two-thirds (2/3) of the votes of the votes cast by holders of Semper Paratus’ ordinary shares present in person or represented by proxy and entitled to vote at the Meeting. The following is a tabulation of the votes with respect to this proposal, which was approved by Semper Paratus’ shareholders: For Against Abstain Broker Non-Votes 13,840,594 143,495 0 n/a
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Tevogen Bio Holdings Inc. shareholders approved Proposal No. 4(B) — Advisory Charter Proposal to provide the alteration of authorized shares of New Tevogen requires affirmative vote of majority of stock authorized to vote at the 2024-01-31 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2024-01-31
Exact text from the filing
A proposal to provide the alteration of authorized shares of New Tevogen requires the affirmative vote of the holders of a majority New Tevogen’s stock authorized to vote: For Against Abstain Broker Non-Votes 13,840,594 143,495 0 n/a
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Tevogen Bio Holdings Inc. shareholders approved Proposal No. 4(E) — Advisory Charter Proposal to eliminate the ability of stockholders to take action by written consent in lieu of a meeting at the 2024-01-31 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2024-01-31
Exact text from the filing
A proposal to eliminate the ability of New Tevogen stockholders to take action by written consent in lieu of a meeting: For Against Abstain Broker Non-Votes 13,840,594 143,495 0 n/a
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Tevogen Bio Holdings Inc. shareholders approved Proposal No. 4(C) — Advisory Charter Proposal to permit removal of a director only for cause and only by affirmative vote of at least two-thirds entitled to vote at the 2024-01-31 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2024-01-31
Exact text from the filing
A proposal to permit removal of a director only for cause and only by the affirmative vote of the holders of at least two-thirds (2/3) entitled to vote at an election of directors of New Tevogen: For Against Abstain Broker Non-Votes 13,840,594 143,495 0 n/a
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Tevogen Bio Holdings Inc. shareholders approved Proposal No. 1 — The Business Combination Proposal — Approval of the Business Combination at the 2024-01-31 meeting.

Proposal
merger approval
Outcome
passed
Meeting
2024-01-31
Exact text from the filing
Proposal No. 1 — The Business Combination Proposal — The approval of the Business Combination Proposal required the affirmative vote of a majority of the votes cast by holders of Semper Paratus’ ordinary shares present in person or represented by proxy and entitled to vote at the Meeting. The following is a tabulation of the votes with respect to this proposal, which was approved by Semper Paratus’ shareholders: For Against Abstain Broker Non-Votes 13,840,594 143,495 0 n/a
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Tevogen Bio Holdings Inc. shareholders approved Proposal No. 4(D) — Advisory Charter Proposal to provide that the number of directors will be fixed from time to time by a majority of the board of directors at the 2024-01-31 meeting.

Proposal
charter amendment
Outcome
passed
Meeting
2024-01-31
Exact text from the filing
A proposal to provide that, subject to the rights of holders of any series of preferred stock, the number of directors will be fixed from time to time by a majority of the board of directors of New Tevogen: For Against Abstain Broker Non-Votes 13,840,594 143,495 0 n/a
View on SEC.gov

151 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Tevogen Bio Holdings Inc. filing history →

Source: SEC EDGAR
accession 0001493152-24-004562
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.